Evaluating and Treating Patients with Mineral and Bone Disorders Associated with Chronic Kidney Disease

Treatment decisions should be based on serial measurements of phosphate, calcium, and parathyroid hormone levels.

Sponsoring Organization: Kidney Disease: Improving Global Outcomes (KDIGO)

Target Audience: Nephrologists, primary care physicians, and others caring for adults with chronic kidney disease (CKD) or on dialysis

Objective: KDIGO has updated its 2009 recommendations (Kidney Int Suppl 2009; 113:S1) on evaluating and treating patients with mineral and bone disorders associated with CKD (CKD-BMD), particularly managing serum phosphate, calcium, and parathyroid hormone (PTH) levels in adults with glomerular filtration rates (GFR) <60 mL/minute/1.73 m².

Key Points

Bone-mineral density (BMD) measurement is not recommended for all patients with CKD but is reasonable if it will affect decisions regarding fall prevention or osteoporosis treatment. Bone bio…

Reviewing Author

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

Evaluating and Treating Patients with Mineral and Bone Disorders Associated with Chronic Kidney Disease

Topics

Key Points

Reviewing Author